Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | CDC25B | P30305 | 2/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876010 | 1.00 | PTPN1 (0.52) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B | |
| SCHEMBL4875999 | 1.00 | PTPN1 (0.52) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B | |
| SCHEMBL4867076 | 0.88 | PIK3CD (0.57) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B | |
| SCHEMBL4867086 | 0.88 | PIK3CD (0.57) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B | |
| SCHEMBL4866081 | 0.88 | CSNK2A2 (0.48) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B | |
| SCHEMBL4866085 | 0.88 | CSNK2A2 (0.48) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B | |
| SCHEMBL27626563 | 0.85 | CSNK2A2 (0.48) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B | |
| SCHEMBL3934386 | 0.82 | CSNK2A2 (0.47) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B | |
| SCHEMBL3934393 | 0.82 | CSNK2A2 (0.47) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B | |
| SCHEMBL3944068 | 0.79 | DYRK1A (0.47) | PTPN1CDC25BDUSP3CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1608365-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | Sucampo AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004087138-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | PTPN1 2962/4885CDC25B 4318/4885DUSP3 1349/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | PTPN1 530/4885CDC25B 4084/4885DUSP3 3857/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | PTPN1 2760/4885CDC25B 4054/4885DUSP3 1933/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | PTPN1 530/4885CDC25B 4084/4885DUSP3 3857/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | PTPN1 1362/4885CDC25B 4582/4885DUSP3 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.